Acquisition Synergy Leverage the 2026 acquisition by Alcanza Clinical Research to cross-sell CNS's high-enrollment, compliant sites to a broader sponsor network and integrate operations for faster multicenter trials.

Regulatory Excellence CNS's record of more than 50 FDA reviews with no findings showcases strong regulatory integrity and patient safety, a compelling differentiator for risk-averse sponsors seeking reliable data and quality control.

Enrollment Advantage Strong patient engagement and fast enrollment performance across CNS sites position the company as a preferred partner for trials that require rapid recruitment and high-quality data.

Geographic Expansion Florida-based presence and potential to expand within Alcanza's network offer a pathway to scale site coverage in strategic regions and support global studies.

Digital Capabilities Existing technology stack can be extended to sponsor-facing dashboards, eConsent, and digital patient recruitment programs, enabling more transparent trial progress and faster time-to-market.